Veropharm posts 1Q 2010 net profit of 121.2 million roubles

Veropharm, a leading Russian pharmaceutical producer, has posted a 1Q 2010 net profit of 121.2 million roubles under IFRS.

The bottom line was down 3.4% from the Net Result of 125.4 million roubles in 1Q 2009, despite EBITDA rising 4.1% year on year to 198.7 million roubles, on the back of a 5.5% in revenues to 963 million roubles.

The company said RX drug sales accounted for 62% of total sales while the share of bandage sales came to 21% while over the counter drugs increased to 16%, with the share of traditional medication sales decreasing to 1%.